Neurotoxicity of isolated limb perfusion with tumor necrosis factor

被引:16
作者
Drory, VE [1 ]
Lev, D
Groozman, GB
Gutmann, M
Klausner, JM
机构
[1] Tel Aviv Univ, Sackler Sch Med, Tel Aviv Sourasky Med Ctr, Dept Neurol, IL-69978 Tel Aviv, Israel
[2] Tel Aviv Univ, Sackler Sch Med, Tel Aviv Sourasky Med Ctr, EMG Lab, IL-69978 Tel Aviv, Israel
[3] Tel Aviv Univ, Sackler Sch Med, Tel Aviv Sourasky Med Ctr, Dept Surg BC, IL-69978 Tel Aviv, Israel
关键词
neuropathy; neurotoxicity; tumor necrosis factor; hyperthermic isolated limb perfusion; chemotherapy;
D O I
10.1016/S0022-510X(98)00098-7
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Hyperthermic isolated limb perfusion (HILP) with tumor necrosis factor alpha (TNF alpha) is effective for advanced melanoma and sarcoma of the limbs. Ten patients undergoing HILP with TNF alpha were evaluated by neurological examinations, nerve conduction studies (NCS), sympathetic skin responses (SSR) and conventional and quantitative electromyography (EMG), performed before, 7 days and 6 weeks following HILP. Seven patients showed minimal clinical signs of peripheral nerve damage following HILP; in two the injury was evident electrophysiologically: 7 days following HILP five patients had paresthesias and/or hypoesthesia, one had a mild foot drop and one had autonomic disturbances in the affected limb. SSR was low in two patients in the affected limb, sensory nerve action potentials were not elicited in one, with normal motor NCS and EMG. At 6 weeks, four patients continued to have mild paresthesias and one had dysautonomia of the perfused limb. Sensory responses and SSR did not change, motor abnormalities were not found. These findings show that HILP with TNF alpha induces a mild, mainly sensory neuropathy in perfused limbs, not disturbing functionality and improving over time. (C) 1998 Elsevier Science B.V.
引用
收藏
页码:1 / 4
页数:4
相关论文
共 18 条
[1]   SYMPATHETIC SKIN-RESPONSE - AGE EFFECT [J].
DRORY, VE ;
KORCZYN, AD .
NEUROLOGY, 1993, 43 (09) :1818-1820
[2]  
EDWARDS MJ, 1990, ARCH SURG-CHICAGO, V125, P317
[3]  
Forman A D, 1994, Oncology (Williston Park), V8, P105
[4]   Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: Results of a tumor necrosis factor dose-escalation study [J].
Fraker, DL ;
Alexander, HR ;
Andrich, M ;
Rosenberg, SA .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (02) :479-489
[5]   ANTITUMOR-ACTIVITY OF MURINE TUMOR NECROSIS FACTOR (TNF) AGAINST TRANSPLANTED MURINE TUMORS AND HETEROTRANSPLANTED HUMAN-TUMORS IN NUDE-MICE [J].
HARANAKA, K ;
SATOMI, N ;
SAKURAI, A .
INTERNATIONAL JOURNAL OF CANCER, 1984, 34 (02) :263-267
[6]  
HOEKSTRA HJ, 1993, CANCER, V72, P1224, DOI 10.1002/1097-0142(19930815)72:4<1224::AID-CNCR2820720415>3.0.CO
[7]  
2-B
[8]   HIGH-DOSE RECOMBINANT TUMOR-NECROSIS-FACTOR-ALPHA IN COMBINATION WITH INTERFERON-GAMMA AND MELPHALAN IN ISOLATION PERFUSION OF THE LIMBS FOR MELANOMA AND SARCOMA [J].
LIENARD, D ;
EWALENKO, P ;
DELMOTTE, JJ ;
RENARD, N ;
LEJEUNE, FJ .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (01) :52-60
[9]   Ischemic reperfusion causes lipid peroxidation and fiber degeneration [J].
Nagamatsu, M ;
Schmelzer, JD ;
Zollman, PJ ;
Smithson, IL ;
Nickander, KK ;
Low, PA .
MUSCLE & NERVE, 1996, 19 (01) :37-47
[10]   VASCULAR CHANGES AND DEMYELINATION INDUCED BY THE INTRANEURAL INJECTION OF TUMOR-NECROSIS-FACTOR [J].
REDFORD, EJ ;
HALL, SM ;
SMITH, KJ .
BRAIN, 1995, 118 :869-878